Aquestive Therapeutics, Inc. (NASDAQ:AQST) Position Increased by MetLife Investment Management LLC

MetLife Investment Management LLC boosted its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 86.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 36,096 shares of the company’s stock after buying an additional 16,716 shares during the quarter. MetLife Investment Management LLC’s holdings in Aquestive Therapeutics were worth $180,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in AQST. BNP Paribas Financial Markets boosted its position in shares of Aquestive Therapeutics by 252.2% in the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after buying an additional 13,481 shares during the period. Quantbot Technologies LP purchased a new stake in Aquestive Therapeutics in the 3rd quarter worth about $135,000. Charles Schwab Investment Management Inc. boosted its position in Aquestive Therapeutics by 4.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock worth $1,014,000 after acquiring an additional 9,268 shares during the period. Intech Investment Management LLC purchased a new position in Aquestive Therapeutics during the 3rd quarter valued at about $90,000. Finally, GSA Capital Partners LLP grew its stake in Aquestive Therapeutics by 525.5% during the 3rd quarter. GSA Capital Partners LLP now owns 137,151 shares of the company’s stock valued at $683,000 after acquiring an additional 115,223 shares in the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ AQST opened at $3.89 on Tuesday. The business has a 50 day simple moving average of $4.92 and a 200 day simple moving average of $4.04. Aquestive Therapeutics, Inc. has a 52 week low of $1.84 and a 52 week high of $6.23. The stock has a market cap of $354.69 million, a price-to-earnings ratio of -8.64 and a beta of 2.63.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $13.54 million for the quarter, compared to the consensus estimate of $12.69 million. During the same period last year, the company earned ($0.03) earnings per share. On average, analysts predict that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on AQST. Leerink Partners raised their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. JMP Securities reiterated a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research note on Wednesday, November 6th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Aquestive Therapeutics has an average rating of “Buy” and an average target price of $9.80.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.